Illumina Stock Crashes 19% Despite Beating Earnings and Raising Guidance

Illumina stock fell 18.6% on Friday, October 30, 2026, closing at $235.99 — even though the DNA sequencing company beat earnings estimates and raised its full-year guidance. The drop of $54.07 from Thursday's close of $290.06 was one of the steepest in the S&P 500 that day, and it shows how unforgiving this earnings season has become: a good quarter was not enough for a stock that had already run up more than 157% since February.

What happened, in direct terms

Illumina reported third-quarter results on Thursday, October 29, and the shares crashed the next session. The headline numbers were mixed in a way that confused the first read. On a reported GAAP basis, revenue was $1.129 billion, below the roughly $1.15 billion analysts expected. Excluding tariff refunds recognized in the quarter, non-GAAP revenue was $1.166 billion — above that same estimate. Earnings, by contrast, beat clearly: GAAP diluted earnings per share were $1.43, and non-GAAP earnings per share excluding tariff refunds were $1.44, ahead of the $1.36 consensus and up 7.5% from a year earlier, according to Investor's Business Daily and the company's release summarized by StockStory.

Underneath the tariff noise, the business grew in line with plan. Evercore ISI analyst Vijay Kumar noted that sales grew 4.8% organically, ahead of Illumina's own guidance for 4.5% organic growth, with demand driven by placements of the NovaSeq X sequencing platform and the consumables each test requires.

Illumina raised guidance — and sold off anyway

Management raised, not cut, the outlook. Full-year 2026 revenue guidance rose by $30 million at the midpoint to between $4.64 billion and $4.66 billion, and diluted earnings guidance rose to between $5.40 and $5.45 per share. Fourth-quarter revenue was guided to $1.22 billion to $1.24 billion, and the company reiterated a forecast for mid-single-digit sales growth in 2027.

So why the crash? Three things stacked up. First, the tariff-refund accounting made the reported revenue line look like a miss, and in a nervous market the first read is often the trade. Second, management highlighted impacts from Illumina's placement on China's Unreliable Entities List, a reminder that one of its important markets carries political risk that guidance cannot fully capture. Third, expectations were elevated: the stock had surged more than 157% from its February 12 low of $112.65 to Thursday's close, and was still up about 75% for the year even after Friday's fall. As Barron's put it in its Friday movers roundup, Illumina raised its outlook and beat earnings estimates, but that was not enough to escape the broader technology selloff — the same session in which Intel fell nearly 29% and the Nasdaq dropped 2.86%.

Why this is blowing up

Illumina became Friday's clearest example of a pattern running through this earnings season: investors are punishing anything ambiguous, however strong the underlying numbers. A revenue figure that could be read as either a miss or a beat depending on tariff treatment, a China warning, and a stock priced after a 157% run were enough to erase nearly a fifth of the company's value in one day.

Analysts were more measured than the market. JPMorgan lowered its price target to $300 from $320 but kept an overweight rating, a target that still implies roughly 27% upside from the previous close, according to MarketBeat reporting via The Lincolnian. Canaccord Genuity kept a hold rating with a $300 target, and Robert W. Baird maintained a hold as well. In other words, the professional downgrade was a trimming of targets, not a break in the story — the share price move was far larger than the analyst moves that followed it.

What to watch next

The next test is execution against the raised numbers: fourth-quarter revenue of $1.22 billion to $1.24 billion, continued NovaSeq X adoption — the platform already accounted for the large majority of high-throughput sequencing volume — and any further disclosure on China, where the Unreliable Entities List designation remains the biggest known unknown. Friday's close at $235.99 also left the stock about 20% below its October 52-week high of $293.69, so the market has reset expectations sharply; whether that reset was an overreaction depends on the December quarter, not on Friday's tariff-distorted revenue line. This post reports what happened and why markets reacted; it is not a recommendation to buy, sell, or hold any security.

FAQ

Why did Illumina stock fall 18.6% on Friday?

Reported GAAP revenue of $1.129 billion looked like a miss against roughly $1.15 billion expected, management flagged impacts from China's Unreliable Entities List, and the stock had already risen more than 157% since February, leaving it exposed in a broad tech selloff.

Did Illumina beat earnings estimates in Q3 2026?

Yes on earnings: non-GAAP EPS excluding tariff refunds was $1.44 versus $1.36 expected. Revenue was split — $1.129 billion GAAP, or $1.166 billion excluding tariff refunds, bracketing the $1.15 billion estimate.

Did Illumina raise or cut its guidance?

It raised it: full-year revenue guidance rose $30 million at the midpoint to $4.64 billion to $4.66 billion, with EPS guidance of $5.40 to $5.45 and fourth-quarter revenue guided to $1.22 billion to $1.24 billion.

What did analysts do after the drop?

JPMorgan cut its price target to $300 from $320 while keeping an overweight rating; Canaccord Genuity and Robert W. Baird held their hold ratings, so analyst moves were far smaller than the 18.6% share-price fall.